IDEAYA Initiates Phase 1 Study of IDE892 plus RG6505 in 40% MTAP-Deleted Pancreatic Cancer
IDYA•IDEAYA Biosciences will sponsor a Phase 1 trial combining its PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. MTAP deletion occurs in up to 40% of PDAC and the collaboration includes joint governance and potential triplet evaluation with IDE397.
1. Collaboration Details
IDEAYA Biosciences entered a clinical collaboration with Roche to test IDE892, its potential best-in-class PRMT5 inhibitor, in combination with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. Under the agreement, IDEAYA will sponsor the study while Roche supplies RG6505, and each company retains commercial rights to its respective compounds.
2. Trial Design and Oversight
The study employs a Phase 1 dose escalation design in MTAP-deleted solid tumors, with combination cohorts launching in pancreatic ductal adenocarcinoma. A joint governance committee of IDEAYA and Roche representatives will oversee safety assessments, efficacy evaluations, and overall study conduct.
3. Scientific Rationale
MTAP deletions are present in up to 40% of pancreatic ductal adenocarcinoma and nearly all MTAP-deleted tumors harbor co-occurring RAS mutations. Preclinical data showed robust tumor regressions with IDE892 monotherapy, and pairing with RG6505 may enhance response depth and durability in this genetically defined population.
4. Future Development Plans
The collaboration framework allows for potential evaluation of a triplet regimen combining IDE892, RG6505, and IDE397, IDEAYA’s Phase 2 MAT2A inhibitor, upon joint approval. IDEAYA also plans to expand combination cohorts into non-small cell lung cancer and other MTAP-deleted solid tumor indications.
